TrialBMC infectious diseases2023

Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.

B Cosmi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.